Price
No data yet.
Social Signal Score
Revenue
$129.86MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Todd Franklin Watanabe
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 354
- Beta
- 1.53
- Country
- US
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 5.67
Financials
Revenue
$129.86M+17811.9%Net Income
$15.01MEBITDA
$17.15M+31657.4%Free Cash Flow
$12.48MEPS (diluted)
$0.11Shares Outstanding (diluted)
135.90M+12769.1%Operating Expenses
$102.49MCash & Debt
$238.55MRevenue by Segment (annual)
$59.61MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $376.07M | $-16.14M | $-0.13 |
| 2024 | $196.54M | $-140.04M | $-1.16 |
| 2023 | $59.61M | $-262.14M | $-3.78 |
| 2022 | $3.69M | $-311.46M | $-5.66 |
| 2021 | $0.00 | $-206.36M | $-4.17 |
| 2020 | $0.00 | $-135.68M | $-3.80 |
| 2019 | $0.00 | $-42.00M | $-1.10 |
| 2018 | $0.00 | $-19.25M | $-0.53 |
| 2017 | $0.00 | $-4.98M | $-4.71 |
Valuation
ARQThas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
90Social Signal Score
Mentions (1)
- Newszacks.com·6h ago·Negative
5 Biotech Stocks Worth Adding to Your Portfolio Now New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position HALO, RGEN, IOVA, ARQT and PGEN in this volatile sector.
View source ↗
Earnings
Tue, Oct 27(in 2 months)
Consensus estimate $0.17 per share
Typical surprise +67.9% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$0.11 vs $0.06beat
- Wed, May 6$-0.09 vs $-0.02miss
- Wed, Feb 25$0.13 vs $0.03beat
- Tue, Oct 28$0.06 vs $-0.10beat
- Wed, Aug 6$-0.13 vs $-0.18beat
- Tue, May 6$-0.20 vs $-0.21beat
Estimates and results for ARQT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ARQT officers and directors.
- Bought
- —
- Sold
- $5.8m
0 trades
40 trades
- Curran Terriesold
- Burnett Patricksold
- Welgus Howard G.sold
- Burnett Patricksold
- Burnett Patricksold
- Burnett Patricksold
- Matsuda Masarusold
- Watanabe Toddsold
60 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.